Denemek ALTIN - Özgür

From Hazy to Crystal Clear Picture of Compensation Trends

BioSpectrum Asia

|

July 2022

The Life Sciences industry is, indeed, growing at a rapid speed, with every region reporting bonuses and salary increments, as well as a high demand in recruiting new talent. With the talent market becoming increasingly hot, it is critical for industry hiring managers and companies to stay highly aware of compensation trends in the Asia Pacific (APAC) region. Let's assess the current scenario to get a handle on 'what's changed'.

- Kayleigh Regan,

From Hazy to Crystal Clear Picture of Compensation Trends

Compensation is always tricky to determine, both as a professional and for organisations. Across all markets, individuals and businesses regularly ask for the very latest compensation trends to benchmark and identify where they stand in the market. We have surveyed over 400 life sciences professionals across APAC, and the results are insightful.

Australia

Australia's life sciences sector has been a long success story for its economy - employing over 240,000 people and accounting for AUD 3 billion in exports each year. The ASX-listed Australian life sciences sector is worth AUD 100 billion and comprises about 100 companies. With world-leading medical and scientific research bases, excellent institutions, a growing biotech sector, as well as an adaptive healthcare system, government initiatives and strong workforce, Australia's life sciences market is remaining on track for huge potential growth.

The majority of life sciences professionals in Australia have received a 0-5 per cent salary yearly increment in 2021. However, with a small talent pool, we are seeing companies willing to offer up to a 20 per cent salary increase to candidates to move on from their existing employers. Especially with the scarcity of talent, more counteroffers are given by existing companies to limit leavers.

Most of the life sciences talent in Australia are comfortable with where they are and will only move if the opportunity is attractive enough. The advice to life sciences professionals is to keep an eye on the market trends and to understand the market average rate. To hiring managers, it is highly recommended to work closely with your talent partner to make sure your offer is attractive to the right people and competitive enough for your preferred candidate, not only so you can hire in a timely manner, but so you can avoid counter offers which are increasingly happening.

Hong Kong

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size